A systematic review of the effect of compound <i>Danshen</i> dripping pills combined with conventional Western medicine treatment on inflammatory factors and cardiac function after percutaneous coronary intervention for acute myocardial infarction_Chinese Journal of Evidence-Based Medicine

Authors：

ZHONG Changming ¹ , SHI Zhaofeng ¹ , DAI Qianqian ¹ , ZHAO Chen ³ ,  SHANG Hongcai ^1,2

1. Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, P.R. China;
2. International Evidence-based Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, P.R. China;
3. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, P.R. China;

Corresponding?author：

SHANG Hongcai, Email: shanghongcai@foxmail.com

Keywords：

Acute myocardial infarction; Percutaneous coronary intervention (PCI); Cardiac function; Inflammatory cytokine; Randomized controlled trial; Systematic review

DOI：

10.7507/1672-2531.202101083

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the effect of compound Danshen dripping pills combined with Western medicine on inflammatory factors and cardiac function after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction.Methods Databases including CNKI, WanFang Data, VIP, CBM, PubMed, Web of Science, EMbase and The Cochrane Library were searched for randomized controlled trials of compound Danshen dripping pills combined with Western medicine in the treatment of acute myocardial infarction after PCI. The retrieval time was from the establishment of the databases to June 11^th, 2020. Two reviewers independently screened literature, extracted data and evaluated the risk bias of included studies. RevMan 5.3 software was used for meta-analysis.Results A total of 16 studies were included, involving 2 069 patients. The results of the meta-analysis showed that the combination of compound Danshen dripping pills could increase the left ventricular ejection fraction (MD =?4.74, 95%CI 4.07 to 5.42, P<0.01), decrease the B-type natriuretic peptide (SMD=?3.81, 95%CI ?5.06 to ?2.57, P<0.01), the level of interleukin-6 (SMD=?3.20, 95%CI ?4.54 to ?1.86, P<0.01) and level of tumor necrosis factor-a (SMD=?4.96, 95%CI ?7.03 to ?2.89, P<0.01).Conclusions Current evidence suggests that the combination of compound Danshen dropping pills has potential benefits in inhibiting inflammation and improving cardiac function after PCI. Due to the limited quality and quantity of the included studies, more high-quality studies are required to verify the above conclusions.

Citation： ZHONG Changming, SHI Zhaofeng, DAI Qianqian, ZHAO Chen, SHANG Hongcai. A systematic review of the effect of compound Danshen dripping pills combined with conventional Western medicine treatment on inflammatory factors and cardiac function after percutaneous coronary intervention for acute myocardial infarction. Chinese Journal of Evidence-Based Medicine, 2021, 21(6): 662-668. doi: 10.7507/1672-2531.202101083 Copy

1.	中華醫學會心血管病學分會, 中華心血管病雜志編輯委員會, 中國循環雜志編輯委員會. 急性心肌梗死診斷和治療指南. 中華心血管病雜志, 2001, 29(12): 710-725.
2.	Hamasaki S, Tei C. Effect of coronary endothelial function on outcomes in patients undergoing percutaneous coronary intervention. J Cardiol, 2011, 57(3): 231-238.
3.	Chang SM, Yazbek N, Lakkis NM. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv, 2004, 62(2): 193-197.
4.	陸勇良. 阿托伐他汀鈣片對行 PCI 術 ACS 患者炎癥反應及血管內皮功能的影響分析. 中國現代藥物應用, 2018, 12(11): 119-20.
5.	尋玉君, 單鵬. 他汀類藥物的不良反應評價. 國際醫藥衛生導報, 2019, (16): 2764-2766.
6.	Luo J, Xu H, Chen K. Systematic review of compound danshen dropping pill: a Chinese patent medicine for acute myocardial infarction. Evid Based Complement Alternat Med, 2013, 2013: 808076.
7.	馬世堂, 戴國梁, 程小桂, 等. 基于系統虛擬藥理學復方丹參滴丸抗血小板聚集藥效物質基礎研究. 中藥材, 2018, 41(1): 189-194.
8.	梁茜, 李煒杰, 楊希立, 等. 復方丹參滴丸改善心肌缺血再灌注損傷研究進展. 中國現代藥物應用, 2020, 14(7): 236-238.
9.	中華醫學會心血管病學分會. 心血管疾病防治指南和共識. 北京: 人民衛生出版社, 2010,.
10.	Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from: www.training.cochrane.org/handbook.
11.	張天嵩. 經典 Meta 分析統計模型的合理選擇. 中國循證醫學雜志, 2020, 20(12): 1477-1481.
12.	陳宏, 魏冬梅, 于麗, 等. 復方丹參滴丸對老年急性心肌梗死患者 PCI 術后血清炎癥因子及T細胞亞群的影響. 中國老年學雜志, 2018, 38(11): 2586-2588.
13.	陳儉. 復方丹參滴丸對急性經皮冠狀動脈介入術后心功能改善的影響. 航空航天醫學雜志, 2020, 31(1): 75-77.
14.	方芳, 甘受益, 馮光瑞, 等. 長期服用復方丹參滴丸對老年急性心肌梗死患者 PCI 術后左室重構及炎癥因子水平的影響. 現代生物醫學進展, 2017, 17(3): 544-546, 566.
15.	付文輝. 復方丹參滴丸對急性心梗患者 PCI 術后 BNP 水平及心室重塑的影響研究. 山西職工醫學院學報, 2019, 29(4): 54-56.
16.	戢艷瓊, 李梓香, 左金梅. 經皮冠狀動脈介入術后應用復方丹參滴丸輔助治療急性心肌梗死的療效觀察. 內科急危重癥雜志, 2019, 25(3): 243-245.
17.	李丹芳. 復方丹參滴丸聯合阿托伐他汀改善急性心肌梗死 PCI 術后炎性反應和心肌灌注的臨床療效. 心腦血管病防治, 2018, 18(6): 500-502.
18.	李廣平, 鄭心田, 王懷禎, 等. 復方丹參滴丸對急性 ST 段抬高心肌梗死介入治療的臨床作用. 中國介入心臟病學雜志, 2011, 19(1): 24-28.
19.	李紅宇. 丹參滴丸對急性心肌梗死患者血漿 BNP 及 TNF-a 水平和心功能的影響研究. 中國醫藥指南, 2013, 11(25): 17-18.
20.	牛瑞剛. 復方丹參滴丸聯合瑞舒伐他汀對 PCI 術后老年急性心肌梗死病人心功能及炎性因子的影響. 中西醫結合心腦血管病雜志, 2020, 18(7): 1110-1113.
21.	歐更, 姜明燕, 郜琪臻, 等. 老年心肌梗死患者 PCI 術后心率變異性的變化及丹參滴丸的臨床療效研究. 現代生物醫學進展, 2017, 17(1): 59-61, 47.
22.	石新景. 丹參滴丸聯合氯吡格雷治療急性心肌梗死的研究. 實用中西醫結合臨床, 2020, 20(3): 63-64.
23.	蘇新生. 復方丹參滴丸對急性心肌梗死患者經皮冠狀動脈介入治療術后腦鈉肽水平及心室重塑的影響. 中國實用醫刊, 2019, 46(12): 110-114.
24.	許小進, 張一炎, 張蘇潔, 等. 復方丹參滴丸聯合瑞舒伐他汀對急性心肌梗死經皮冠狀動脈介入術后左心室重構及心肌纖維化的影響. 中國醫藥導報, 2019, 16(35): 61-64, 77.
25.	張亞運. 復方丹參滴丸對急性 ST 段抬高型心肌梗死患者直接 PCI 療效的影響. 太原: 山西醫科大學, 2017.
26.	張怡, 伏曉琳, 劉博, 等. 丹參滴丸對急性 ST 段抬高型心肌梗死 PCI 術后心肌保護作用. 中國醫藥導報, 2018, 15(34): 153-156, 60.
27.	周祥群, 陳海金, 劉尚軍, 等. 丹參滴丸聯合強化降脂治療對急性心肌梗死 PCI 術后再梗死的預防作用研究. 中華中醫藥學刊, 2017, 35(10): 2699-2702.
28.	Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation, 1979, 59(3): 607-609.
29.	中華醫學會心血管病學分會, 中華心血管病雜志編輯委員會. 急性 ST 段抬高型心肌梗死診斷和治療指南. 中華心血管病雜志, 2015, 43(5): 380-393.
30.	中華醫學會心血管病學分會, 中華心血管病雜志編輯委員會. 急性 ST 段抬高型心肌梗死診斷和治療指南. 中華心血管病雜志, 2010, 38(8): 675-690.
31.	Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Can J Cardiol, 2004, 20(10): 977-1025.
32.	沈衛峰, 張奇, 張瑞巖, 等. 2015 年急性 ST 段抬高型心肌梗死診斷和治療指南解析. 國際心血管病雜志, 2015, 42(4): 217-9.
33.	Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res, 2012, 110(1): 159-173.
34.	Yokoyama T, Vaca L, Rossen RD, et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest, 1993, 92(5): 2303-2312.
35.	Goldhaber J I. Free radicals enhance Na+/Ca2+ exchange in ventricular myocytes. Am J Physiol, 1996, 271(3 Pt 2): H823-833.
36.	曹珊, 許梅, 張湘燕, 等. 丹參減輕炎性因子-炎癥反應作用探討. 現代中西醫結合雜志, 2019, 28(11): 1251-1254.
37.	黃家林, 田代雄. 三七總皂苷抗炎免疫藥理研究進展. 中華中醫藥雜志, 2016, 31(11): 4657-4660.
38.	孫淑萍, 杜云艷, 鎖孝國, 等. 冰片對脂多糖誘導的 RAW264.7 巨噬細胞炎癥模型的影響. 通化師范學院學報, 2019, 40(4): 61-68.
39.	潘潔麗, 郟國炯, 王萌. 中藥制劑復方丹參滴丸對急性心肌梗死患者體內核因子-κB p65 介導的炎癥反應的影響. 藥物生物技術, 2017, 24(2): 120-123.

1. 中華醫學會心血管病學分會, 中華心血管病雜志編輯委員會, 中國循環雜志編輯委員會. 急性心肌梗死診斷和治療指南. 中華心血管病雜志, 2001, 29(12): 710-725.
2. Hamasaki S, Tei C. Effect of coronary endothelial function on outcomes in patients undergoing percutaneous coronary intervention. J Cardiol, 2011, 57(3): 231-238.
3. Chang SM, Yazbek N, Lakkis NM. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv, 2004, 62(2): 193-197.
4. 陸勇良. 阿托伐他汀鈣片對行 PCI 術 ACS 患者炎癥反應及血管內皮功能的影響分析. 中國現代藥物應用, 2018, 12(11): 119-20.
5. 尋玉君, 單鵬. 他汀類藥物的不良反應評價. 國際醫藥衛生導報, 2019, (16): 2764-2766.
6. Luo J, Xu H, Chen K. Systematic review of compound danshen dropping pill: a Chinese patent medicine for acute myocardial infarction. Evid Based Complement Alternat Med, 2013, 2013: 808076.
7. 馬世堂, 戴國梁, 程小桂, 等. 基于系統虛擬藥理學復方丹參滴丸抗血小板聚集藥效物質基礎研究. 中藥材, 2018, 41(1): 189-194.
8. 梁茜, 李煒杰, 楊希立, 等. 復方丹參滴丸改善心肌缺血再灌注損傷研究進展. 中國現代藥物應用, 2020, 14(7): 236-238.
9. 中華醫學會心血管病學分會. 心血管疾病防治指南和共識. 北京: 人民衛生出版社, 2010,.
10. Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from: www.training.cochrane.org/handbook.
11. 張天嵩. 經典 Meta 分析統計模型的合理選擇. 中國循證醫學雜志, 2020, 20(12): 1477-1481.
12. 陳宏, 魏冬梅, 于麗, 等. 復方丹參滴丸對老年急性心肌梗死患者 PCI 術后血清炎癥因子及T細胞亞群的影響. 中國老年學雜志, 2018, 38(11): 2586-2588.
13. 陳儉. 復方丹參滴丸對急性經皮冠狀動脈介入術后心功能改善的影響. 航空航天醫學雜志, 2020, 31(1): 75-77.
14. 方芳, 甘受益, 馮光瑞, 等. 長期服用復方丹參滴丸對老年急性心肌梗死患者 PCI 術后左室重構及炎癥因子水平的影響. 現代生物醫學進展, 2017, 17(3): 544-546, 566.
15. 付文輝. 復方丹參滴丸對急性心梗患者 PCI 術后 BNP 水平及心室重塑的影響研究. 山西職工醫學院學報, 2019, 29(4): 54-56.
16. 戢艷瓊, 李梓香, 左金梅. 經皮冠狀動脈介入術后應用復方丹參滴丸輔助治療急性心肌梗死的療效觀察. 內科急危重癥雜志, 2019, 25(3): 243-245.
17. 李丹芳. 復方丹參滴丸聯合阿托伐他汀改善急性心肌梗死 PCI 術后炎性反應和心肌灌注的臨床療效. 心腦血管病防治, 2018, 18(6): 500-502.
18. 李廣平, 鄭心田, 王懷禎, 等. 復方丹參滴丸對急性 ST 段抬高心肌梗死介入治療的臨床作用. 中國介入心臟病學雜志, 2011, 19(1): 24-28.
19. 李紅宇. 丹參滴丸對急性心肌梗死患者血漿 BNP 及 TNF-a 水平和心功能的影響研究. 中國醫藥指南, 2013, 11(25): 17-18.
20. 牛瑞剛. 復方丹參滴丸聯合瑞舒伐他汀對 PCI 術后老年急性心肌梗死病人心功能及炎性因子的影響. 中西醫結合心腦血管病雜志, 2020, 18(7): 1110-1113.
21. 歐更, 姜明燕, 郜琪臻, 等. 老年心肌梗死患者 PCI 術后心率變異性的變化及丹參滴丸的臨床療效研究. 現代生物醫學進展, 2017, 17(1): 59-61, 47.
22. 石新景. 丹參滴丸聯合氯吡格雷治療急性心肌梗死的研究. 實用中西醫結合臨床, 2020, 20(3): 63-64.
23. 蘇新生. 復方丹參滴丸對急性心肌梗死患者經皮冠狀動脈介入治療術后腦鈉肽水平及心室重塑的影響. 中國實用醫刊, 2019, 46(12): 110-114.
24. 許小進, 張一炎, 張蘇潔, 等. 復方丹參滴丸聯合瑞舒伐他汀對急性心肌梗死經皮冠狀動脈介入術后左心室重構及心肌纖維化的影響. 中國醫藥導報, 2019, 16(35): 61-64, 77.
25. 張亞運. 復方丹參滴丸對急性 ST 段抬高型心肌梗死患者直接 PCI 療效的影響. 太原: 山西醫科大學, 2017.
26. 張怡, 伏曉琳, 劉博, 等. 丹參滴丸對急性 ST 段抬高型心肌梗死 PCI 術后心肌保護作用. 中國醫藥導報, 2018, 15(34): 153-156, 60.
27. 周祥群, 陳海金, 劉尚軍, 等. 丹參滴丸聯合強化降脂治療對急性心肌梗死 PCI 術后再梗死的預防作用研究. 中華中醫藥學刊, 2017, 35(10): 2699-2702.
28. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation, 1979, 59(3): 607-609.
29. 中華醫學會心血管病學分會, 中華心血管病雜志編輯委員會. 急性 ST 段抬高型心肌梗死診斷和治療指南. 中華心血管病雜志, 2015, 43(5): 380-393.
30. 中華醫學會心血管病學分會, 中華心血管病雜志編輯委員會. 急性 ST 段抬高型心肌梗死診斷和治療指南. 中華心血管病雜志, 2010, 38(8): 675-690.
31. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Can J Cardiol, 2004, 20(10): 977-1025.
32. 沈衛峰, 張奇, 張瑞巖, 等. 2015 年急性 ST 段抬高型心肌梗死診斷和治療指南解析. 國際心血管病雜志, 2015, 42(4): 217-9.
33. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res, 2012, 110(1): 159-173.
34. Yokoyama T, Vaca L, Rossen RD, et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest, 1993, 92(5): 2303-2312.
35. Goldhaber J I. Free radicals enhance Na+/Ca2+ exchange in ventricular myocytes. Am J Physiol, 1996, 271(3 Pt 2): H823-833.
36. 曹珊, 許梅, 張湘燕, 等. 丹參減輕炎性因子-炎癥反應作用探討. 現代中西醫結合雜志, 2019, 28(11): 1251-1254.
37. 黃家林, 田代雄. 三七總皂苷抗炎免疫藥理研究進展. 中華中醫藥雜志, 2016, 31(11): 4657-4660.
38. 孫淑萍, 杜云艷, 鎖孝國, 等. 冰片對脂多糖誘導的 RAW264.7 巨噬細胞炎癥模型的影響. 通化師范學院學報, 2019, 40(4): 61-68.
39. 潘潔麗, 郟國炯, 王萌. 中藥制劑復方丹參滴丸對急性心肌梗死患者體內核因子-κB p65 介導的炎癥反應的影響. 藥物生物技術, 2017, 24(2): 120-123.

Chinese Journal of Evidence-Based Medicine

A systematic review of the effect of compound Danshen dripping pills combined with conventional Western medicine treatment on inflammatory factors and cardiac function after percutaneous coronary intervention for acute myocardial infarction

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content